Grace Therapeutics, Inc. Comprehensive Income
Grace Therapeutics, Inc. (GRCE) reported Comprehensive Income of -$15.79 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-13
- Grace Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$15.79M.
- Grace Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$1.18M, a 285.22% decline year-over-year.
- Grace Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$2.31M.
- Grace Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$938.00K.
- Grace Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2026 was -$7.79M.
- Grace Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$9.57M.
- Grace Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$12.85M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$15.79M 10-Q · filed 2026-08-13 | -$16.97M derived: sum of 2 quarters · filed 2026-08-13 | -$19.28M derived: sum of 3 quarters · filed 2026-08-13 | -$20.22M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | -$3.49M derived: sum of 2 quarters · filed 2026-06-18 | -$4.43M derived: sum of 3 quarters · filed 2026-06-18 | -$7.79M 10-K · filed 2026-06-18 |
| 2025-12-31 | -$2.31M 10-Q · filed 2026-02-12 | -$3.25M derived: sum of 2 quarters · filed 2026-02-12 | -$6.62M 10-Q · filed 2026-02-12 | -$5.98M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-09-30 | -$938.00K 10-Q · filed 2025-11-13 | -$4.30M 10-Q · filed 2025-11-13 | -$3.66M derived: sum of 3 quarters · filed 2026-08-13 | -$7.82M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$3.36M 10-Q · filed 2026-08-13 | -$2.73M derived: sum of 2 quarters · filed 2026-08-13 | -$6.88M derived: sum of 3 quarters · filed 2026-08-13 | -$10.31M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $636.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | -$3.52M derived: sum of 2 quarters · filed 2026-06-18 | -$6.95M derived: sum of 3 quarters · filed 2026-06-18 | -$9.57M 10-K · filed 2026-06-18 |
| 2024-12-31 | -$4.16M 10-Q · filed 2026-02-12 | -$7.59M derived: sum of 2 quarters · filed 2026-02-12 | -$10.20M 10-Q · filed 2026-02-12 | -$13.37M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-09-30 | -$3.43M 10-Q · filed 2025-11-13 | -$6.05M 10-Q · filed 2025-11-13 | -$9.21M derived: sum of 3 quarters · filed 2025-11-13 | -$11.61M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$2.62M 10-Q · filed 2025-08-12 | -$5.78M derived: sum of 2 quarters · filed 2025-08-12 | -$8.17M derived: sum of 3 quarters · filed 2025-08-12 | -$11.45M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$3.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-23 | -$5.56M derived: sum of 2 quarters · filed 2025-06-23 | -$8.83M derived: sum of 3 quarters · filed 2025-06-23 | -$12.85M 10-K · filed 2025-06-23 |
| 2023-12-31 | -$2.39M 10-Q · filed 2025-02-13 | -$5.66M derived: sum of 2 quarters · filed 2025-02-13 | -$9.69M 10-Q · filed 2025-02-13 | |
| 2023-09-30 | -$3.27M 10-Q · filed 2025-02-13 | -$7.30M 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | -$4.02M 10-Q · filed 2025-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |